Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort 24-week encore results to be presented in a poster .
ReNAgade Therapeutics a company unlocking the limitless potential for RNA medicines today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene Cell Therapy ASGCT 27th Annual Meeting being held May 711 2024 in Baltimore Maryland.
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with